HMGCR and Miyoshi myopathy: Standard-dose simvastatin (SD-Sim) is well tolerated without grade 3/4 toxicity and shows reduction of cell adhesion-mediated drug resistance in MM by inhibition of HMG-CoA-reductase. Moreover, authors suggest that SD-Sim efficacy needs to be improved either by dose escalation and/or by combination with other mevalonate pathway inhibitors